Eight companies – Arrowhead Pharmaceuticals, Endeavour BioMedicines, Enterprise Therapeutics, Insilico Medicine, ReCode Therapeutics, Sionna Therapeutics, Verona Pharma, and Vicore Pharma – are advancing novel therapies for respiratory diseases, with a focus on cystic fibrosis and idiopathic pulmonary fibrosis. These firms are leveraging technologies like RNAi, hedgehog inhibitors, ENaC inhibitors, AI-developed small molecules, and gene therapies to create innovative treatments.
Reimagining healthcare cybersecurity: Insights from Gen. Paul Nakasone at HIMSS25
At the HIMSS25 Global Conference, former NSA Director General Paul M. Nakasone discussed how artificial intelligence (AI) is transforming healthcare. He highlighted AI’s potential to
